1584 - CARISEL A Hybrid III Implementation Effectiveness Study of implementation of Cabotegravir plus Rilpivirine Long Acting (CAB+RPV LA) in EU Health Care Settings Key Clinical and Implementation Outcomes by Implementation Arm

Co-Author(s)

• SD

  Stephane De Wit, PhD

  Saint-Pierre University Hospital, Université Libre de Bruxelles
  Brussels, Brussels Hoofdstedelijk Gewest, Belgium

  Disclosure: Disclosure(s): AstraZeneca: Grant/Research Support ()

  Slides
• AR

  Agathe Rami, PhD

  GH Lariboisière Fernand Widal
  Paris, Ile-de-France, France

  Disclosure: Disclosure(s): No financial relationships to disclose
• FB

  Fabrice Bonnet, PhD

  CHU de Bordeaux, Hôpital Saint André
  Bordeaux, Aquitaine, France

  Disclosure: Disclosure(s): Gilead: Grant/Research Support (), Honoraria (); MSD: Grant/Research Support (), Honoraria (); ViiV Healthcare: Grant/Research Support (), Honoraria ()
• RD

  Rebecca DeMoor, M.S.

  GlaxoSmithKline
  Collegeville, Pennsylvania, United States

  Disclosure: Disclosure(s): GlaxoSmithKline: Employee ()
• GB

  Gilda Bontempo, MD

  ViiV Healthcare
  Branford, Connecticut, United States

  Disclosure: Disclosure(s): ViiV Healthcare: Employee (), Stocks/Bonds ()
• CL

  Christine Latham, MS

  ViiV Healthcare
  Durham, North Carolina, United States

  Disclosure: Disclosure(s): ViiV Healthcare: Employee (), Stocks/Bonds ()
• MG

  Martin Gill, BSc

  GlaxoSmithKline
  Brentford, England, United Kingdom

  Disclosure: Disclosure(s): GlaxoSmithKline: Employee ()
• MH

  Monica Hadi, PhD

  Evidera
  London, England, United Kingdom

  Disclosure: Disclosure(s): Evidera: Employee ()
• OC

  Owen Cooper, DPsych

  Evidera
  London, England, United Kingdom

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• SA

  Savita Bakhshi Anand, PhD

  Evidera
  London, England, United Kingdom

  Disclosure: Disclosure(s): Evidera: Employee ()
• CG

  Cassidy Gutner, PhD

  ViiV Healthcare
  Durham, North Carolina, United States

  Disclosure: Disclosure(s): ViiV Healthcare: Employee ()
• 

  Mounir Ait-Khaled, PhD

  Clinical Science Director
  ViiV Healthcare, Brentford, UK
  Brentford, England, United Kingdom

  Disclosure: Disclosure(s): GlaxoSmithKline: Stocks/Bonds (); ViiV Healthcare: Employee ()
• Jv

  Jean A. van Wyk, MB,ChB; MFPM

  Global Medical Lead, VP
  ViiV Healthcare Limited
  Brentford, England, United Kingdom

  Disclosure: Disclosure(s): ViiV Healthcare Limited: I am an employee of ViiV Healthcare (), Stocks/Bonds ()

Presenting Author(s)

• 

  Maggie Czarnogorski, MD MPH

  Head, Innovation and Implementation Science
  ViiV Healthcare
  Research Triangle Park, NC, United States

  Disclosure: Disclosure(s): ViiV Healthcare: Employee (), Stocks/Bonds ()

  Slides